Nuovi criteri orientativi per l’uso appropriato della diagnostica allergologica in vitro 4.0. Parte 1: diagnostica di base e avanzata

AUTORI

ABSTRACT

Updted creteria for the appropriate use of in vitro allergy diagnostics 4.0. Part 1: basic and advanced diagnostic

Allergic diseases are among the top chronic diseases in Europe and developing countries, and the World Health Organisation now considers allergy a ‘non-communicable, out-of-control disease’ with a possible increase in prevalence of up to 50% in the latest generation. Allergology transversally involves different medical specialities, affecting different organs and apparatuses and opening up to numerous varieties of clinical pictures. In parallel, the Allergy Diagnostic Laboratory is assuming a major role in helping to provide a personalised, targeted and accurate approach for the allergic patient, based on the preliminary detection of an individual sensitisation profile. The aim of this document is to illustrate the whole range of new resources that Laboratory Medicine can provide for initial diagnostic guidance for Allergy, directing selected patients into the appropriate pathway, and referring those who really need an accurate specialist examination to the allergist. In a following document (part 2), specific allergies will be considered: food allergies, allergies to hymenoptera venoms and professional allergies (i.e. latex).

BIBLIOGRAFIA

1 Muraro A. EAACI Advocacy Manifesto. Tackiling the allergy crisis in Europee www.veroval.info/EEACI_Advocacy_Manifesto
2 Coombs RR, Gell PG. : Classification of allergicreactions responsible for clinical hypersensitivity and disease. In: Gell PG, Coombs RR, Edts, Clinical Aspectsof Immunology, Oxford: Blackwell, 1963.
3 Faggian D, Brusca I, Cinti B, Caruso B, Dente B, Mazzarello MG, et al. per il Gruppo di Studio SIBioC “Allergologia di Laboratorio. Determinazione delle immunoglobuline E specifiche. Biochim Clin 2018; 42: 74-78

4 Pascal M, Moreno C, Dávila I, Tabar AI, Bartra J, Labrador M et al. Integration of in vitro allergy test resalts and ratio analysis for the diagnosis and treatment of allergic patients (INTEGRA). Clin Transl Allergy 2021; e12052
5 Pascal M, Moreno C, Dávila I, Tabar AI, Bartra J, Labrador M, et al. Integration of in vitro allergy test resalts and ratio analysis for the diagnosis and treatment of allergic patients (INTEGRA). Clin Transl Allergy 2021;e12052.
6 Zetterström O, Johansson SGO. IgE concentrations measured by PRIST in serum of healthy adults and in patients with respiratory allergy. Allergy 1981;36:537–47.
7 Faggian D. Valutazione del sistema UNICAP 1000 per il dosaggio in completa automazione delle IgE specifiche. Biochim Clin 2004;28:337-44.
8 Vlieg-Boerstra BJ, van de Weg WE, van der Heide S, Dubois AE. Where to prick the apple for skin testing? Allergy 2013;681196-8.
9 Clinical and Laboratory Standard Institute (CLSI). Analytical Performance Characteristics and Clinical Utility of Immunological Assays for Human Immunoglobulin E (IgE) Antibodies and Defined Allergen Specificities; approved guideline. CLSI document I/LA20. CLSI Wayne, PA, 2016.
10 Yman L. Standardization of in vitro methods. Allergy 2001;56:70-4.
11 Ahlstedt S. Understanding the usefulness of specific IgE blood tests in allergy. Clin Exp All 2002;32:11-6.
12 Johansson SGO. ImmunoCAP Specific IgE test: an objective for research and routine allergy diagnosis. Exprt Rev Mol Diagn 2004;4:270-3.
13 Thorpe S, Heath A, Fox B, Patel D, Egner W The 3rd International Standard for serum IgE: international collaborative study to evaluate a candidate preparation. Clin Chem Lab Med 2014;52:1283-9.
14 Wood RA, Segall N, Ahlstedt S, Williams PB . Accuracy of IgE antibody laboratory results. Ann Allergy Asthma Immunol 2007;99:34-41.
15 Pal B. Szecsi, Stender S. Comparison of immunoglobulin e measurements on immulite and immunocap in samples consisting of allergen-specific mouse-human chimeric monoclonal antibodies towards allergen extracts and four recombinant allergens. Int Arch Allergy Immunol 2013;162:131-4.
16 Schwartz, LB. Diagnostic Value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451-63.
17 Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Imm 2012;157:215-25.
18 Akin C and Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin N Am 2014;34:207-18.
19 Ruëff, F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, et.al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: Importance of baseline serum tryptase –a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009;124:1047-54.
20 Simons FE, Ardusso LR, Bilò MB, Cardona V , Ebisawa M, El-Gamal YM et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014;7:9.
21 Simons FE, Ardusso LR, Dimov V, Ebisawa M, El-Gamal YM, Lockey RFet.al. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 2013;162:193-204.
22 Ruëff, F, Vos B, Oude Elberink J, Bender A, Chatelain R, Dugas-Breit S, et.al. Predictors of clinical effectiveness of hymenoptera venom immunotherapy. Clin and experimental allergy 2014;44:736-46.
23 Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 2013;3:159-72.
24 Carter MC, Metcalfe DD, Komarow HD. Mastocytosis. Immunology and allergy clinics of North America 2014 34:181-96.
25 Florian S, Krauth MT, Simonitsch-Klupp I. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005;136:273-80.
26 Frieri M, Quershi M.. Pediatric Mastocytosis: a review of the literature. Pediatr Allergy Immunol Pulmonol 2013;26:175-80.
27 González de Olano D, de la Hoz Caballer B, Núñez López R. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37:1547-55.
28 Brockow K, Jofer C Behrendt JH, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-32.
29 Alvarez-Twose I, de Olano DG, Sánchez-Muñoz L,Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125:1269-78.
30 Carter MC,Metcalfe DD. Paediatric mastocytosis. Arch Dis Child 2002;86:315-9.
31 Schwartz LB, Yunginger JW, Miller JS, Bokhari R, Dull D The time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989;83:1551-5.
32 Min H, Moxley G, Neale MC, Schwartz LB. Effect of sex and haplotype on plasma tryptase levels in healthy adults. J Allergy Clin Immunol 2004;114:48-51.
33 Komarow HD, Hu Z, Brittain E, Uzzaman A, Gaskins D, Metcalfe DD Serum tryptase levels in atopic and nonatopic children. J Allergy Clin Immunol 2009;124:845-7.
34 Metcalfe DD. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc 2005;116:185-204.
35 Schwartz LB, Lewis RA, Austen KF. Tryptase from human pulmonary mast cells. J Biol Chem 1981;256:11939-43.
36 Pereira PJ, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, Sommerhoff CP, Bode W. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Nature 1998; 392:306-11.
37 Yunginger JW, Nelson DR, Squillace DL, Jones RT, Holley KE, Hyma BA et al Laboratory Investigation of Deaths Due to Anaphylaxis. J Forensic Sci 1991;36 857-65.
38 Low I, Stables S. Anaphylactic deaths in Auckland, New Zealand: a review of coronial autopsies from 1985 to 2005. Pathology 2006;38:328-32.
39 Van der Linden PWG, Hack CE, Poortman J, Vivié-Kipp YC, Struyvenberg A, van der Zwan JK Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation. J Allergy Clin Immunol 1992;90:110-8.
40 Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S et.al. Serum Tryptase Levels in Patients with Mastocytosis: Correlation with mast Cell Burden and Implication for Defining the Category of Disease. Int Arch Allergy Immunol 2002;128:136-41.
41 Moscato G, Pala G, Cullinan P, Folletti I, Gerth van Wijk R, Pignatti P, et al. EAACI Position Paper on assessment of cough in the workplace. Allergy 2014;69:292-304
42 Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017;129:1420-7.
43 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le BeauMM, et al. The 2016 revision to the World Health Organization classificationof myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405
44 Horny HP, Akin C, Arber D, et al. Mastocytosis. In: Swerdlow SH,Campo E, Harris NL, et al, eds. World Health Organization (WHO) Classificationof Tumours. Pathology & Genetics. Tumours of Haematopoieticand Lymphoid Tissues. Lyon, France: IARC Press; 2016.
45 Badar A, Saeed W, Hussain MM, Aslam M. Correlation of eosinophil cationic proteinwith severity of asthma. J Ayub Med Coll Abbottabad 2004;16:66-71.
46 Koh YY, Kang H, Kim CK. Ratio of serum eosinophil cationic protein/blood eosinophilcounts in children with asthma: comparison between acute exacerbation and clinicalremission. Allergy Asthma Proc 2003;24:269-74.
47 Joseph-Bowen J, de Klerk N, Holt PG, Sly PD. Relationship of asthma, atopy, and bronchial responsiveness to serum eosinophil cationic proteins in early childhood. J Allergy Clin Immunol 2004;114:1040-5.
48 Chen FJ, Liao H, Huang XY, Xie CM. Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma. J ThoracDis 2016;8:992-9.
49 Rubio A., Vivinus-Nébot M., Bourrier T. Saggio B, Albertini M, Bernard A. Benefit of the basophil activation test in deciding when to reintroduce cow’s milk in allergic children. Allergy 2011;66:92-100.
50 Asero R. Plant Food Allergies: A suggested approach to Allergen-Resolved Diagnosis in the clinical practice by identifyng easily available sensitization markers. Int Arch Allergy Immunol 2005;138:1-11.
51 Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012:366:489-91.
52 WHO – IUIS Allergen nomenclature – www.allergen.org (ultmo accsso: novembre 2023).
53 Allergen Enciclopedia. Scientific Information on Whole Allergens and Allergen Components. https://www.thermofisher.com/diagnostic-education/hcp/gb/en/resource-center/allergen-encyclopedia.html (ultmo accsso: novembre 2023).
54 Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy 2010;40:1442-60.
55 Luengo O, Cardona V. Component resolved diagnosis: when should it be used? Clin Transl Allergy.2014;4:28
56 Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R . Recombinant Marker Allergens: Diagnostic Gatekeepers for the Treatment of Allergy. Int Arch Allergy Immunol 2002;127:259-68
57 Batard T, Baron-Bodo V, Martelet A, Le Mignon M, Lemoine P, Jain K et al. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Allergy 2016;71:220-9.
58 Weghofer M, Grote M, Resch Y, Casset A, Kneidinger M, Kopec J et al. Identification of Der p 23, a Peritrophin-like Protein, as a New Major Dermatophagoides pteronyssinus Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets. J Immunol 2013;190:3059-67.
59 Mueller GA, Randall TA, Glesner J, Pedersen LC, Perera L, Edwards LL et al. Serological, genomic, and structural analyses of the major mite allergen Der p 23. Clin Exp Allergy 2016; 46:365-76.
60 Resch Y, Weghofer M, Seiberler S, Horak F, Scheiblhofer S, Linhart B et al. Molecular characterization of Der p 10: a diagnostic marker for broad sensitization in house dust mite allergy. Clin Exp Allergy 2011;41:1468-77.
61 Mattsson L, Lundgren T, Everberg H, Larsson H, Lidholm J. Prostatic kallikrein: a new major dog allergen. J Allergy Clin Immunol 2009;123:362-8.
62 Bjerg A, Winberg A, Berthold M, Mattsson L , Borres MP , Rönmark E A population-based study of animal component sensitization, asthma, and rhinitis in schoolchildren. Pediatr Allergy Immunol 2015;26:557-63.
63 Asero R, Conte M, Senna GE. Features of sensitization to airborne allergens among extra-European immigrants living in 2 distinct areas of Northern Italy. Eur Ann Allergy Clin Immunol. 2012;44:183-7.
64 Zahradnik E, Raulf M. Respiratory allergens from furred mammals: environmental and occupational exposure. Vet Sci 2017;4:38.
65 Nwaru BI, Suzuki S, Ekerljung L, Sjölander S, Mincheva R, Rönmark EP et al. Furry animal allergen component sensitization and clinical outcomes in adult asthma and rhinitis. J Allergy Clin Immunol Pract 2019;7:1230-8
66 Uriarte SA, Sastre J. Clinical relevance of molecular diagnosis in pet allergy. Allergy 2016;71:1066-8.
67 Ukleja-Sokolowska N, Gawronska-Ukleja E, Zbikowska-Gotz M, Socha E, Lis K, Sokołowski Ł, Kuźmiński A et al. Analysis of feline and canine allergen components in patients sensitized to pets. Allergy Asthma Clin Immunol 2016;12:61.
68 Basagana M, Luengo O, Labrador M, Garriga T, Mattsson L, Lidholm J et al. Component-Resolved Diagnosis of Dog Allergy. J Investig Allergol Clin Immunol 2017;27:185-7.
69 Feo Brito F, Alonso AM, Carnés J, Martín-Martín R, Fernández-Caldas E, Galindo PA,. Correlation between Alt a 1 levels and clinical symptoms in Alternaria alternate monosensitized patients. J investing Allergol Clin Immunol 2012;22:154-9.
70 Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE, et al. A WAO – ARIA – GA²LEN consensus document on molecular-based allergy diagnostics. World Allergy Organization Journal 2013;6:17.
71 Crameri R, Hemmann S, Ismail C, Menz G, Blaser K. . Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. Int Immunol 1998;10:1211-6.
72 Andersson K, Lidholm J. Characteristics and immunology of Grass Pollen Allergens. Int Arch Allergy Immunol 2003;130:87-107.
74 Tripodi S, Frediani T, Lucarelli S, Macrì F, Pingitore G, Di Rienzo Businco A et al. Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: Implications for specific immunotherapy. J Allergy Clin Immunol 2012;129: 834-49.
73 Valenta R, Twaroch T, Swoboda I. Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area. J Investig Allergol Clin Immunol 2007;17:36-40
75 Vieths S, Scheurer S, Ballmer-Webe B. Current understanding of cross-reactivity of food allergens and pollen. Ann N.Y Acad Sci 2002; 964:47-68